Should I buy or sell Coeptis Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Coeptis Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" COEP shares. View COEP analyst ratings or view top-rated stocks .

What is Coeptis Therapeutics' stock price target for 2024?

1 equities research analysts have issued 1-year price targets for Coeptis Therapeutics' stock. Their COEP share price targets range from $3.00 to $3.00. On average, they expect the company's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 782.1% from the stock's current price. View analysts price targets for COEP or view top-rated stocks among Wall Street analysts .

How have COEP shares performed in 2024?

Coeptis Therapeutics' stock was trading at $0.7839 at the beginning of 2024. Since then, COEP shares have decreased by 56.6% and is now trading at $0.3401. View the best growth stocks for 2024 here .

Are investors shorting Coeptis Therapeutics?

Coeptis Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 107,700 shares, an increase of 171.3% from the March 15th total of 39,700 shares. Based on an average trading volume of 239,400 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.5% of the company's shares are short sold. View Coeptis Therapeutics' Short Interest .

When is Coeptis Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our COEP earnings forecast .

How were Coeptis Therapeutics' earnings last quarter?

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) posted its quarterly earnings data on Monday, March, 25th. The company reported ($0.08) earnings per share for the quarter.

How do I buy shares of Coeptis Therapeutics?

Shares of COEP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:COEP

Coeptis Therapeutics (COEP) Stock Price, News & Analysis

→ Your Next Portfolio Star: Revealing 2024's Top Stock Pick (From Darwin) (Ad)

Free COEP Stock Alerts

$0.34

-0.01 (-3.11%)

(As of 02:04 PM ET)

Compare

Today's Range: $0.34
▼
$0.38
50-Day Range: $0.30
▼
$0.58
52-Week Range: $0.29
▼
$2.19

Volume: 146,017 shs
Average Volume: 244,173 shs
Market Capitalization: $12.27 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.50

Get Coeptis Therapeutics alerts:

Coeptis Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 782.1% Upside
$3.00 Price Target
Short Interest: Healthy
0.47% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.20 out of 5 stars

Medical Sector

619th out of 918 stocks

Biological Products, Except Diagnostic Industry

102nd out of 151 stocks

3.5

Analyst's Opinion

Consensus Rating
Coeptis Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Coeptis Therapeutics has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.47% of the float of Coeptis Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Coeptis Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Coeptis Therapeutics has recently increased by 171.28%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Coeptis Therapeutics does not currently pay a dividend.
Dividend Growth
Coeptis Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for COEP.

0.6

News and Social Media Coverage

Search Interest
4 people have searched for COEP on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Coeptis Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Coeptis Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
21.49% of the stock of Coeptis Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 13.88% of the stock of Coeptis Therapeutics is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Coeptis Therapeutics is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Coeptis Therapeutics is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Coeptis Therapeutics has a P/B Ratio of 2.62. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad The Bull Report

Healthcare Takes A Big Step Forward With The Help Of AI

The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.

Click here to see why this small company is trusted by the Mayo Clinic

About Coeptis Therapeutics Stock (NASDAQ:COEP)

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. is headquartered in Wexford, Pennsylvania.

COEP Stock Price History

30 days | 90 days | 365 days | Advanced Chart

COEP Stock News Headlines

April 11, 2024 | americanbankingnews.com

Short Interest in Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Grows By 171.3%

April 9, 2024 | americanbankingnews.com

Comparing Coeptis Therapeutics (COEP) and Its Peers

April 19, 2024 | DTI (Ad)

Did you know you can now trade Bitcoin in your regular brokerage account?

You see, thanks to one unique investor's brand new discovery - anyone with a regular brokerage account can now tap into the most explosive asset in history! That means you can skip the hassle of opening a Coinbase account… Bypass the fees and hard-to-remember passwords… Heck, you don’t even need a crypto wallet!

April 2, 2024 | prnewswire.com

Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award

April 1, 2024 | investorplace.com

COEP Stock Earnings: Coeptis Therapeutics Beats EPS for Q4 2023

February 28, 2024 | investing.com

Coeptis expands license for CAR technology to autoimmune diseases

February 26, 2024 | finance.yahoo.com

Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK

February 26, 2024 | prnewswire.com

Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK

April 19, 2024 | DTI (Ad)

This company has increased its dividend every year for 54 years

There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.

February 17, 2024 | morningstar.com

Coeptis Therapeutics Holdings Inc Ordinary Shares COEP

February 7, 2024 | finance.yahoo.com

Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections

February 2, 2024 | msn.com

Coeptis Therapeutics Risks Nasdaq Delisting Over Bid Price

January 4, 2024 | finance.yahoo.com

Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024

December 9, 2023 | benzinga.com

Coeptis Therapeutics Stock (NASDAQ:COEP) Insider Trades

December 4, 2023 | finance.yahoo.com

Coeptis Therapeutics to Present at the Emerging Growth Conference

November 15, 2023 | markets.businessinsider.com

Buy Rating for Coeptis Therapeutics Holdings Amidst Promising Cancer Cell Therapy Platforms and Exclusive Licensing Assets

October 31, 2023 | finance.yahoo.com

Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023

October 24, 2023 | msn.com

Coeptis Therapeutics to raise $2M in a private placement

October 24, 2023 | finance.yahoo.com

Coeptis Therapeutics Announces $2 Million Private Placement

October 11, 2023 | bizjournals.com

Local pharma firm widens technology deal with the University of Pittsburgh

October 11, 2023 | markets.businessinsider.com

Coeptis Expands License Agreement With University Of Pittsburgh To Include SNAP-CAR Platform

October 9, 2023 | finance.yahoo.com

Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene Therapies

October 4, 2023 | finance.yahoo.com

Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting

September 27, 2023 | finance.yahoo.com

Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the Mesa

September 20, 2023 | msn.com

Seattle biotech startup Deverra Therapeutics raising cash to develop cellular immunotherapies

September 14, 2023 | finance.yahoo.com

Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection

September 11, 2023 | finance.yahoo.com

Coeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research Endowment

See More Headlines

Receive COEP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Coeptis Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/25/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:COEP
CUSIP: N/A
CIK: 1759186
Web: coeptispharma.com
Phone: 724-934-6467
Fax: N/A
Employees: 4
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $3.00
High Stock Price Target: $3.00
Low Stock Price Target: $3.00
Potential Upside/Downside: +929.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.84)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-21,270,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -794.75%
Return on Assets: -322.86%

Debt

Debt-to-Equity Ratio: 0.03
Current Ratio: 1.76
Quick Ratio: 1.76

Sales & Book Value

Annual Sales: $80,000.00
Price / Sales: 153.43
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.13 per share
Price / Book: 2.62

Miscellaneous

Outstanding Shares: 36,090,000
Free Float: 28,334,000
Market Cap: $12.27 million
Optionable: Not Optionable
Beta: -0.89

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Mr. David Mehalick (Age 55)
Co-Founder, Chairman of the Board, CEO & President
Comp: $361.62k
Ms. Christine Elise Sheehy (Age 57)
Co-Founder and VP of Compliance & Corporate Secretary
Comp: $226k
Mr. Daniel Alexander Yerace (Age 41)
Co-Founder, VP of Operations & Director
Comp: $360.35k
Mr. Brian Cogley M.B.A. (Age 38)
Chief Financial Officer
Dr. Colleen Delaney M.D. (Age 57)
M.Sc., CSO & Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

COEP Stock Analysis - Frequently Asked Questions

Should I buy or sell Coeptis Therapeutics stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Coeptis Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" COEP shares.
View COEP analyst ratings or view top-rated stocks.
What is Coeptis Therapeutics' stock price target for 2024?: 1 equities research analysts have issued 1-year price targets for Coeptis Therapeutics' stock. Their COEP share price targets range from $3.00 to $3.00. On average, they expect the company's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 782.1% from the stock's current price.
View analysts price targets for COEP or view top-rated stocks among Wall Street analysts.
How have COEP shares performed in 2024?: Coeptis Therapeutics' stock was trading at $0.7839 at the beginning of 2024. Since then, COEP shares have decreased by 56.6% and is now trading at $0.3401.
View the best growth stocks for 2024 here.
Are investors shorting Coeptis Therapeutics?: Coeptis Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 107,700 shares, an increase of 171.3% from the March 15th total of 39,700 shares. Based on an average trading volume of 239,400 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.5% of the company's shares are short sold.
View Coeptis Therapeutics' Short Interest.

When is Coeptis Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our COEP earnings forecast.
How were Coeptis Therapeutics' earnings last quarter?: Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) posted its quarterly earnings data on Monday, March, 25th. The company reported ($0.08) earnings per share for the quarter.
How do I buy shares of Coeptis Therapeutics?: Shares of COEP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:COEP) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial